Bone Water and Mineralization Measured by Nuclear Magnetic Resonance

Bone Water and Mineralization Measured by Nuclear Magnetic Resonance
Recruiting
50 years - 75 years
Female
Phase N/A
60 participants needed
1 Location

Brief description of study

Post-menopausal osteoporosis is a major public health issue affecting millions of women. However, the microstructural implications of the disorder on cortical bone, the dominant bone type of the skeleton, are poorly understood and currently cannot be evaluated in vivo. This study, which utilizes new quantitative MRI methods, provides a path toward both clinical assessment of cortical bone health and the effectiveness of drug intervention in patients with osteoporosis. All subjects meeting the enrollment criteria at screening will receive bone mineral density scans of the lumbar vertebrae (lateral and AP) and proximal femur quantified by DXA and 3D bone mineral density scans of the mid-shaft tibia by pQCT and acquisition of MR images of the left mid-shaft tibia. Comprehensive metabolic panel (CMP), 25-OH Vitamin D, FSH (at baseline only), parathyroid hormone, and HbA1c will be checked at baseline, 12 and 24 months. Subjects with osteoporosis will receive zoledronic acid infusion annually. Labs will be done at the screening visit and at the 12 month visit to ensure that subjects are healthy to receive infusion. All study participants will receive 1200 mg of calcium and 1000 units of Vitamin D. DXA, pQCT and MRI will be repeated at 12 and 24 months.

Detailed description of study

Requirements, Group 1:
Post-menopausal, osteoporotic women (group 1): 50-75 years old,  BMD T-score less than or equal to -2.5 (at either spine, total hip or femoral neck), 25 vitamin D level greater than 20 ng/ml, serum FSH concentrations of 25 mIU/mL, BMI less than or equal to 30.

Study visits, Group 1: Screening visit (DXA, labs, pQCT, height and weight, urine pregnancy test), Baseline visit (MRI, zoledronic acid infusioin, supplements), 3/6/9 month telephone visit, 12 month visit 1 (height and weight, labs, DXA, pQCT), 12 month visit 2 (MRI, zoledronic acid infusion, supplements), 15/18/21 month telephone visit, 24 month visit (height and weight, labs, DXA, pQCT MRI) **weekly telephone adherence

Requirements, Group 2:
Post-menopausal, control women (group 2): 50-75 years old,  BMD T-score greater than -2.5 (at either spine, total hip or femoral neck), 25 vitamin D level greater than 20 ng/ml, serum FSH concentrations of 25 mIU/mL, BMI less than or equal to 30.

Study visits, Group 2: Screening visit (DXA, labs, pQCT, height and weight, urine pregnancy test), Baseline visit (MRI, supplements), 6 month telephone visit, 12 month visit (height and weight, labs, DXA, pQCT, MRI, supplements), 18 month telephone visit, 24 month visit (height and weight, labs, DXA, pQCT MRI) **weekly telephone adherence


**Weekly telephone adherence- brief phone call/email from coordinator to discuss compliance of taking supplements

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Postmenopausal,Osteoporosis,Healthy Control,Healthy Volunteer
  • Age: 50 years - 75 years
  • Gender: Female
Updated on 19 Feb 2024. Study ID: 825750

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.